PMC10016350_01
Computed tomography scans of the targeted lesion. (A) Baseline. (B) After three doses of pembrolizumab, demonstrating a partial response (PR) of the lesion in the pancreas. (C) After six doses of treatment, the lesion was enlarged.
fonc-13-1118633-g001.jpg
PMC10016350_01_fonc-13-1118633-g001.jpg
f1
After three doses, a CT scan was performed on 28 August 2020 and revealed a partial response of the pancreatic lesion ( Figure 1 ).
Cytometry by time-of-flight mass spectrometry (CyTOF) analysis of the immune state of the patient. (A) Frequencies of immune cell subsets in the peripheral blood mononuclear cell (PBMC) of a patient during treatment with pembrolizumab, 0118: before treatment, 0828: when the patient achieved PR, and 1102: when the patient's disease had progressed. The frequencies of B cells, CD4+T cells, CD8+T cells, CD4+gammadeltaT cells, CD8+gammadeltaT cells, CD163+ macrophages, CD169+ macrophages, dendritic cells (DCs), natural killer cells (NKs), and T helper 2 cells (Th2) were analyzed. (B) Uniform Manifold Approximation and Projection (UMAP) displayed the distribution of myeloid cells from the PBMC in the patient. (C) UMAP displayed the distribution of lymphocytes from the PBMC in the patient.
fonc-13-1118633-g002.jpg
PMC10016350_01_fonc-13-1118633-g002.jpg
f2
In order to know further about how the immune state changed in a pancreatic cancer patient who responded to monotherapy with pembrolizumab, we analyzed the immune cells in peripheral blood by cytometry by time-of-flight mass spectrometry (CyTOF) ( Figure 2 ).